JP2024510436A5 - - Google Patents
Info
- Publication number
- JP2024510436A5 JP2024510436A5 JP2023554337A JP2023554337A JP2024510436A5 JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5 JP 2023554337 A JP2023554337 A JP 2023554337A JP 2023554337 A JP2023554337 A JP 2023554337A JP 2024510436 A5 JP2024510436 A5 JP 2024510436A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- degrees
- approximately
- treatment
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162501P | 2021-03-17 | 2021-03-17 | |
| US63/162,501 | 2021-03-17 | ||
| US202163284592P | 2021-11-30 | 2021-11-30 | |
| US63/284,592 | 2021-11-30 | ||
| PCT/US2022/020716 WO2022197901A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510436A JP2024510436A (ja) | 2024-03-07 |
| JP2024510436A5 true JP2024510436A5 (https=) | 2025-03-25 |
Family
ID=81327141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554337A Pending JP2024510436A (ja) | 2021-03-17 | 2022-03-17 | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245711A1 (https=) |
| EP (1) | EP4308162A1 (https=) |
| JP (1) | JP2024510436A (https=) |
| KR (1) | KR20230158033A (https=) |
| AU (1) | AU2022238365A1 (https=) |
| BR (1) | BR112023018607A2 (https=) |
| CA (1) | CA3213744A1 (https=) |
| IL (1) | IL305858A (https=) |
| MX (1) | MX2023010728A (https=) |
| TW (1) | TW202300156A (https=) |
| WO (1) | WO2022197901A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
-
2022
- 2022-03-17 US US18/550,724 patent/US20240245711A1/en active Pending
- 2022-03-17 CA CA3213744A patent/CA3213744A1/en active Pending
- 2022-03-17 BR BR112023018607A patent/BR112023018607A2/pt unknown
- 2022-03-17 MX MX2023010728A patent/MX2023010728A/es unknown
- 2022-03-17 IL IL305858A patent/IL305858A/en unknown
- 2022-03-17 TW TW111109951A patent/TW202300156A/zh unknown
- 2022-03-17 AU AU2022238365A patent/AU2022238365A1/en active Pending
- 2022-03-17 KR KR1020237034937A patent/KR20230158033A/ko active Pending
- 2022-03-17 WO PCT/US2022/020716 patent/WO2022197901A1/en not_active Ceased
- 2022-03-17 EP EP22715444.0A patent/EP4308162A1/en active Pending
- 2022-03-17 JP JP2023554337A patent/JP2024510436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024510436A5 (https=) | ||
| JP2024515829A5 (https=) | ||
| IL305858A (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder | |
| JP2020532531A5 (https=) | ||
| Amin et al. | Success rate of treatments provided for early childhood caries under general anesthesia: a retrospective cohort study | |
| JP2023166406A5 (https=) | ||
| JP2022191257A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2025092508A5 (https=) | ||
| JP2022523726A5 (https=) | ||
| JP2022174207A5 (https=) | ||
| JPWO2023054732A5 (https=) | ||
| NO20055000L (no) | Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger | |
| JP2024543379A5 (https=) | ||
| JP2021523138A5 (https=) | ||
| JP2022552520A5 (https=) | ||
| JP2024523559A5 (https=) | ||
| JP2025508051A5 (https=) | ||
| JP2021532176A5 (https=) | ||
| JP2023011549A5 (https=) | ||
| JP2022538642A5 (https=) | ||
| JP2023527358A5 (https=) | ||
| JP2023520929A5 (https=) | ||
| JP2025502023A5 (https=) | ||
| JP2023506779A5 (https=) |